ENTITY
Shanghai Henlius Biotech

Shanghai Henlius Biotech (2696 HK)

311
Analysis
Health Care • China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
•30 Jun 2024 00:17

Weekly Deals Digest (30 Jun) - China TCM, Henlius, Midea RE, MMG, Aisin, Sanil, Shift Up

Last week, notable developments occurred in Event-Driven (China TCM, Henlius, Midea Real Estate, Best World) and ECM (Sanil, Shift Up, Aisin, MMG).

Logo
518 Views
Share
•29 Jun 2024 15:00

(Mostly) Asia-Pac M&A: TCM, Henlius Bio, Mideal Real Estate, Malaysia Airports, S Line, Best World

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

Logo
636 Views
Share
bullish•Cross Asset Strategy
•29 Jun 2024 08:10

The Heat Is On: News Flow and Sentiment in HONG KONG

China had positive flows into equity ETF's for June and mainland investors continued to direct money to Hong Kong stocks through the Stock Connect...

Logo
673 Views
Share
bearish•Cross Asset Strategy
•27 Jun 2024 12:52•Syndicated

CX Daily: Consumers, Entrepreneurs Give Banks’ Retail Lending a Much-Needed Boost

Retail lending / In Depth: Consumers, entrepreneurs give banks’ retail lending a much-needed boost Despite market saturation stunting the credit...

Logo
226 Views
Share
•26 Jun 2024 08:55

Shanghai Henlius Biotech Privatization (2696.HK) - The Offer Price Is Disappointing

The ​Cancellation Price is 50% lower than Henlius's IPO price, causing losses for long-term players. Remaining public will provide good returns....

Logo
700 Views
Share
x